Clark George C.
Known title: VP, Chief Accounting OfficerCIK: 0001878290
Clark George C.'s purchase track record
Clark George C. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/17/2025 | BHVN | $145K | +38.8% | +2.7% | +10.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| BHVN | ▲ Buy | Option Exercise | 2,500 | $0 | 1/5/2026 | View on chart |
| BHVN | ▼ Sell | Tax Withholding | 1,117 | $11K | 1/5/2026 | View on chart |
| BHVN | ▲ Buy | Open Market | 17,000 | $145K | 11/17/2025 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 2,500 | $0 | 1/5/2025 | View on chart |
| BHVN | ▼ Sell | Tax Withholding | 1,117 | $43K | 1/5/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Biohaven signs $100M deal with Ono for IgG degraders
Biohaven has entered a strategic licensing agreement with Ono Pharma for its IgG degrader technology in Japan and select Asian regions. The deal includes up to $100 million in near-term payments, with $80 million paid upfront. This move expands the company's presence in Asia and supports its lead candidate, BHV-1300, which is currently in Phase 3 trials for Graves' disease.
Biohaven signs $100M deal with Ono for IgG degraders. Biohaven has entered a strategic licensing agreement with Ono Pharma for its IgG degrader technology in Japan and select Asian regions. The deal includes up to $100 million in near-term payments, with $80 million paid upfront. This move expands the company's presence in Asia and supports its lead candidate, BHV-1300, which is currently in Phase 3 trials for Graves' disease.